Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.

Transplantation - 27 Aug 1999

Hsu D H, Shi J D, Homola M, Rowell T J, Moran J, Levitt D, Druilhet B, Chinn J, Bullock C, Klingbeil C

Abstract excerpt

BACKGROUND: An anti-CD3 antibody that reduces cytokine release syndrome (CRS) while maintaining immunosuppression would be a major advance in the treatment of acute allograft rejection. A humanized (Hu) anti-CD3 IgG2 Ab, HuM291 gamma2 M3 (HuM291; Protein Design Labs, Inc., Mountain View, CA), was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Specificity
Share to CD3 Complex
Share to In Vitro Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocyte Activation

Share to Lymphocyte Count

Share to Lymphocyte Depletion

Share to Pan troglodytes

Share to Protein Engineering

Source

Identifiers

PMID: 10480415
DOI: 10.1097/00007890-199908270-00018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-10480415-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.PMID 10480415Read ↗

In vitro characterization of five humanized OKT3 effector function variant antibodies.Semantic proximity Read ↗

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts.Semantic proximity Read ↗

Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.Semantic proximity Read ↗

Manipulating T cell-mediated pathology: Targets and functions of monoclonal antibody immunotherapySemantic proximity Read ↗

cMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pre-Transplant ConditioningSemantic proximity Read ↗

A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG ActivitySemantic proximity Read ↗

Phenotyping of Myeloid-Derived Suppressor Cells in Nonhuman Primates.Semantic proximity Read ↗

Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibodySemantic proximity Read ↗

Loss of Siglec expression on T lymphocytes during human evolutionSemantic proximity Read ↗

Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques.Semantic proximity Read ↗

In vitro and in vivo investigation of a novel monoclonal antibody to plasma cells (W5 mAb).Semantic proximity Read ↗

Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.